Role of targeting nanoparticles for cancer immunotherapy and imaging
Trends in Immunotherapy · 2017
DOI: 10.24294/ti.v1.i3.95 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Immunotherapy, 2017. Verfasst von Ru Wen und 1 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Cancer immunotherapy involves the delivery of immunogenic compounds and/or the priming, or induction, of the body’s natural immune system to target cancer. The use of cancer immunotherapy has led to various means of cancer prevention and treatment that have produced prolonged life expectancy and stabilized disease. Nanoparticles are promising vehicles or adjuvants for effective delivery of therapeutics, antigens, stimulatory effectors, or antibodies for therapeutic invention. Targeting nanoparticles are especially useful due to their capability of accumulating in specific sites of interest like tumors and, thereby, decreasing risks of damage to normal tissue. Targeting can be achieved by incorporation of cell-surface related binding molecules or antibodies. This review explores the role of targeting nanoparticles as delivery or adjuvant systems to modulate immune response; and as imaging tracking systems for cancer.
Zitieren
APA
Wen, R., & Umeano, A. C. (2017). Role of targeting nanoparticles for cancer immunotherapy and imaging. Trends in Immunotherapy. https://doi.org/10.24294/ti.v1.i3.95
Vancouver
Wen R, Umeano AC. Role of targeting nanoparticles for cancer immunotherapy and imaging. Trends in Immunotherapy. 2017. doi:10.24294/ti.v1.i3.95
BibTeX
@article{Wen2017,
author = {Wen, Ru and Umeano, Afoma C},
title = {Role of targeting nanoparticles for cancer immunotherapy and imaging},
journal = {Trends in Immunotherapy},
year = {2017},
doi = {10.24294/ti.v1.i3.95}
}
EUVIMED